Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Blood Culture Collection Strategies for Suspected Bloodstream Infection (SIMPLE-BC)

3 agosto 2026 aggiornato da: Samo Jeverica, Izola General Hospital

Diagnostic Performance of Single-Venipuncture and Sequential Two-Venipuncture Blood Culture Collection Strategies in Adults With Suspected Bloodstream Infection: A Prospective Within-Participant Diagnostic Study

Blood cultures are the reference standard for diagnosing bloodstream infections and are essential for the management of patients with suspected sepsis. Their diagnostic performance depends strongly on the total volume of blood collected, while each additional venipuncture may increase patient discomfort, staff workload, and the opportunity for contamination.

This prospective diagnostic study will evaluate two blood culture collection strategies within the same adult participant. Consecutive patients with a clinical indication for blood culture collection will be enrolled at Izola General Hospital. During the initial venipuncture, two complete blood culture sets, consisting of two aerobic and two anaerobic bottles and approximately 40 mL of blood, will be collected. One additional set, consisting of one aerobic and one anaerobic bottle and approximately 20 mL of blood, will then be collected from a second venipuncture site during the same diagnostic episode, generally within 30-60 minutes according to routine clinical workflow.

The diagnostic performance of the single-venipuncture strategy will be determined from the initial four bottles. The diagnostic performance of the sequential two-venipuncture strategy will be determined from all six bottles. Each participant will therefore serve as their own control. The primary outcome is the paired difference in detection of clinically significant bloodstream pathogens. Secondary outcomes include the incremental diagnostic yield of the additional set, contamination, overall positivity, time to positivity, and the distribution of pathogens and contaminants.

The investigators hypothesize that the single-venipuncture strategy will identify most clinically significant bloodstream pathogens detected by the complete protocol, while the additional set will provide a measurable but limited incremental diagnostic yield.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Bloodstream infections are associated with substantial morbidity and mortality, particularly in patients with sepsis and septic shock. Timely identification of the causative microorganism enables targeted antimicrobial treatment and supports antimicrobial stewardship. Blood cultures remain the microbiological reference standard, but their performance is influenced by pre-analytical factors, particularly the total blood volume collected, the number of culture bottles, timing of collection, and contamination during venipuncture.

Conventional practice commonly involves collection of blood culture sets from two separate venipuncture sites. However, available evidence suggests that total blood volume may contribute more to pathogen detection than the number of venipunctures. Collecting multiple bottles during one venipuncture may simplify the procedure and improve compliance with the intended blood volume, whereas each additional venipuncture creates another opportunity for contamination. Prospective within-participant evidence from routine clinical settings remains limited.

This is a single-center, prospective, within-participant diagnostic study conducted at Izola General Hospital. Consecutive adults for whom the treating physician orders blood cultures as part of routine care will be assessed for eligibility. The clinical indication for blood culture collection and all treatment decisions will remain under the responsibility of the treating team.

During the initial venipuncture, two complete blood culture sets will be collected, comprising two aerobic and two anaerobic bottles with a target total blood volume of approximately 40 mL. During the same diagnostic episode, generally within 30-60 minutes and according to routine clinical workflow, an additional blood culture set comprising one aerobic and one anaerobic bottle with approximately 20 mL of blood will be collected from a different venipuncture site. The complete study collection will therefore consist of six bottles and approximately 60 mL of blood.

The initial four bottles will define the single-venipuncture strategy. All six bottles will define the sequential two-venipuncture strategy. Because both diagnostic strategies are reconstructed from specimens obtained from the same participant, participant-level clinical characteristics are held constant and each participant serves as their own control. The comparison evaluates the incremental contribution of the additional set and cannot separate the effect of the second venipuncture from the effect of the additional 20 mL of blood.

All bottles will be transported, incubated for five days, and processed according to routine microbiology laboratory procedures. Positive cultures will undergo microorganism identification and antimicrobial susceptibility testing when clinically indicated. Isolates will be classified as clinically significant pathogens or contaminants using predefined criteria based on organism identity, the pattern of positive bottles and sets, and available clinical information. The primary analysis will compare participant-level pathogen detection between the initial four-bottle strategy and the complete six-bottle strategy using paired methods.

The study is intended to quantify the diagnostic performance of a simplified collection strategy and the incremental value of the additional blood culture set. The results may inform local blood culture collection policy and future diagnostic stewardship recommendations.

Tipo di studio

Interventistico

Iscrizione (Stimato)

3000

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Izola, Slovenia
        • Izola General Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age 18 years or older.
  • Clinical indication for blood culture collection determined by the treating physician as part of routine care.
  • Planned collection of peripheral blood cultures during the current diagnostic episode.
  • Ability to complete the study collection protocol.
  • Informed consent obtained in accordance with the ethics committee approval and institutional requirements.

Exclusion Criteria:

  • Inability to obtain blood cultures from two separate peripheral venipuncture sites.
  • A clinical condition in which the treating physician considers the additional blood collection inappropriate or unsafe.
  • Inability to obtain the intended blood volume because of failed collection or premature discontinuation.
  • Blood cultures collected exclusively through an intravascular catheter.
  • Declined consent or withdrawal of permission for study participation or use of study data, where applicable.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Standardized Six-Bottle Blood Culture Collection
All participants undergo an initial single venipuncture yielding four blood culture bottles, followed by an additional two-bottle set collected from a second venipuncture site during the same diagnostic episode, generally within 30-60 minutes. Diagnostic results from the initial four bottles are compared with results from all six bottles within the same participant.
Two aerobic and two anaerobic blood culture bottles, targeting approximately 40 mL of blood, are collected during the initial venipuncture. One additional aerobic and one anaerobic bottle, targeting approximately 20 mL, are collected from a different venipuncture site during the same diagnostic episode, generally within 30-60 minutes. The complete collection totals six bottles and approximately 60 mL of blood.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Paired difference in detection of clinically significant bloodstream pathogens
Lasso di tempo: From initial collection through completion of the five-day blood culture incubation period
For each participant, detection of at least one clinically significant bloodstream pathogen using the initial four bottles collected during one venipuncture will be compared with detection using all six bottles collected during the complete sequential protocol. Results will be reported as paired proportions and the absolute paired difference with a 95% confidence interval.
From initial collection through completion of the five-day blood culture incubation period

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incremental diagnostic yield of the additional blood culture set
Lasso di tempo: From initial collection through completion of the five-day blood culture incubation period
Proportion of participants in whom a clinically significant bloodstream pathogen is detected only in the additional two-bottle set and is not detected in the initial four bottles.
From initial collection through completion of the five-day blood culture incubation period
Blood culture contamination
Lasso di tempo: From initial collection through completion of the five-day blood culture incubation period
Participant-level occurrence of one or more isolates classified as contaminants in the initial four-bottle strategy and in the complete six-bottle strategy, according to predefined microbiological and clinical criteria.
From initial collection through completion of the five-day blood culture incubation period
Overall blood culture positivity
Lasso di tempo: From initial collection through completion of the five-day blood culture incubation period
Participant-level detection of any microorganism, including clinically significant pathogens and contaminants, using the initial four bottles and using all six bottles.
From initial collection through completion of the five-day blood culture incubation period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Direttore dello studio: Mladen Gasparini, Izola General Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 agosto 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 gennaio 2028

Date di iscrizione allo studio

Primo inviato

3 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 agosto 2026

Primo Inserito (Effettivo)

7 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

7 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 0120-649/2025-2711-6

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .